drugset / Trial / NCT02091245
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Phase 1
Active not recruiting
16 enrolled
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc · collabWilliam Lawrence and Blanche Hughes Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT-330, may prevent leukemia cells from growing and may lead to the destruction of leukemia cells. It is thought that KPT-330 activates cellular processes that increase the death of leukemia cells. The main goal of this study is to evaluate the side effects of KPT-330 when it is administered to children and adolescents with relapsed or refractory leukemia.
Timeline
- Start
- 2014-03
- Primary completion
- 2018-02
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 30 mg/m2 | — |